Kenvue Inc. (NYSE:KVUE) Shares Acquired by Intech Investment Management LLC

Intech Investment Management LLC increased its stake in Kenvue Inc. (NYSE:KVUE) by 48.2% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 564,279 shares of the company’s stock after buying an additional 183,451 shares during the period. Intech Investment Management LLC’s holdings in Kenvue were worth $10,259,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in KVUE. Manchester Capital Management LLC lifted its position in shares of Kenvue by 80.8% during the first quarter. Manchester Capital Management LLC now owns 1,186 shares of the company’s stock worth $25,000 after purchasing an additional 530 shares during the last quarter. Mather Group LLC. bought a new position in Kenvue during the 1st quarter worth approximately $28,000. MV Capital Management Inc. grew its position in shares of Kenvue by 71.2% in the 1st quarter. MV Capital Management Inc. now owns 1,544 shares of the company’s stock worth $33,000 after acquiring an additional 642 shares in the last quarter. Salomon & Ludwin LLC bought a new stake in shares of Kenvue in the 1st quarter valued at approximately $33,000. Finally, Riverview Trust Co acquired a new stake in shares of Kenvue during the 1st quarter valued at approximately $33,000. 97.64% of the stock is currently owned by institutional investors.

Kenvue Trading Up 0.5 %

Shares of KVUE stock opened at $23.02 on Friday. Kenvue Inc. has a 1 year low of $17.67 and a 1 year high of $23.55. The firm has a market capitalization of $44.08 billion, a PE ratio of 29.51, a price-to-earnings-growth ratio of 2.92 and a beta of 1.40. The stock has a fifty day moving average of $20.92 and a two-hundred day moving average of $19.96. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.68 and a current ratio of 0.99.

Kenvue (NYSE:KVUE) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $0.32 earnings per share for the quarter, topping the consensus estimate of $0.28 by $0.04. The business had revenue of $4 billion during the quarter, compared to the consensus estimate of $3.93 billion. Kenvue had a net margin of 7.23% and a return on equity of 21.80%. The company’s quarterly revenue was down .3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.32 earnings per share. As a group, research analysts expect that Kenvue Inc. will post 1.08 EPS for the current year.

Kenvue Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, August 28th. Investors of record on Wednesday, August 14th were issued a dividend of $0.205 per share. This is a boost from Kenvue’s previous quarterly dividend of $0.20. The ex-dividend date of this dividend was Wednesday, August 14th. This represents a $0.82 annualized dividend and a yield of 3.56%. Kenvue’s payout ratio is presently 105.13%.

Wall Street Analyst Weigh In

KVUE has been the subject of a number of research reports. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $24.00 price objective on shares of Kenvue in a report on Wednesday, August 7th. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Kenvue from $23.00 to $24.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. Citigroup cut their target price on shares of Kenvue from $21.00 to $20.00 and set a “neutral” rating on the stock in a report on Wednesday, July 10th. UBS Group increased their price target on Kenvue from $20.00 to $22.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 7th. Finally, JPMorgan Chase & Co. boosted their price objective on Kenvue from $22.00 to $24.00 and gave the company an “overweight” rating in a research report on Wednesday, August 7th. One analyst has rated the stock with a sell rating, six have given a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $21.44.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.